- Home
- SCHW vs AMGN Comparison
SCHW vs AMGN Comparison
Compare SCHW & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCHW
- AMGN
- Stock Information
- Founded
- SCHW 1971
- AMGN 1980
- Country
- SCHW United States
- AMGN United States
- Employees
- SCHW N/A
- AMGN N/A
- Industry
- SCHW Investment Bankers/Brokers/Service
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCHW Finance
- AMGN Health Care
- Exchange
- SCHW Nasdaq
- AMGN Nasdaq
- Market Cap
- SCHW 133.5B
- AMGN 156.2B
- IPO Year
- SCHW 1987
- AMGN N/A
- Fundamental
- Price
- SCHW $84.44
- AMGN $265.86
- Analyst Decision
- SCHW Buy
- AMGN Buy
- Analyst Count
- SCHW 15
- AMGN 19
- Target Price
- SCHW $88.73
- AMGN $324.37
- AVG Volume (30 Days)
- SCHW 9.1M
- AMGN 2.7M
- Earning Date
- SCHW 04-17-2025
- AMGN 05-01-2025
- Dividend Yield
- SCHW 1.28%
- AMGN 3.58%
- EPS Growth
- SCHW 38.09
- AMGN 56.16
- EPS
- SCHW 3.30
- AMGN 10.94
- Revenue
- SCHW $20,465,000,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- SCHW $17.66
- AMGN $7.19
- Revenue Next Year
- SCHW $10.59
- AMGN $2.37
- P/E Ratio
- SCHW $25.62
- AMGN $24.29
- Revenue Growth
- SCHW 10.86
- AMGN 15.56
- 52 Week Low
- SCHW $61.01
- AMGN $253.30
- 52 Week High
- SCHW $85.19
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- SCHW 68.09
- AMGN 34.80
- Support Level
- SCHW $82.04
- AMGN $268.81
- Resistance Level
- SCHW $85.19
- AMGN $291.61
- Average True Range (ATR)
- SCHW 1.55
- AMGN 7.54
- MACD
- SCHW 0.56
- AMGN -0.76
- Stochastic Oscillator
- SCHW 92.32
- AMGN 0.76
About SCHW Charles Schwab Corporation (The)
Charles Schwab operates in brokerage, wealth management, banking, and asset management. It runs a large network of brick-and-mortar brokerage branch offices and a well-established online investing website, and it has mobile trading capabilities. It also operates a bank and a proprietary asset-management business and offers services to independent investment advisors. Schwab is among the largest firms in the investment business, with over $10 trillion of client assets at the end of 2024. Nearly all of its revenue is from the United States.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.